All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Income Statement(in thousands, except share and per share data)Three Months Ended September 30,Nine Months Ended September 30,2013201220132012(Unaudited)REVENUE
—COST OF GOODS SOLD
701—869—RESEARCH AND DEVELOPMENT EXPENSES
1,7802,1995,9835,636GENERAL AND ADMINISTRATIVE EXPENSES
2,1131,5067,2524,488SALES AND MARKETING EXPENSES
8,4175,20826,22013,828INTEREST EXPENSE AND OTHER
(134)(186)(397)(629)UNREALIZED FOREIGN CURRENCY GAIN, NET
508—552—CHANGE IN FAIR VALUE OF DERIVATIVE WARRANT
6,229—(6,107)—LOSS ON EARLY EXTINGUISHMENT OF DEBT
(14,457)ACCRETION OF PREFERRED STOCK BENEFICIAL
|SOURCE Alimera Sciences, Inc.|
Copyright©2012 PR Newswire.
All rights reserved